
AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Nova, you need to believe its metrology tools remain essential as chips become more complex across advanced DRAM, gate all around, and advanced packaging. The key short term catalyst is continued order strength from these advanced customers, while the biggest risk is concentration in a handful of large chipmakers whose CapEx can swing quickly. The latest record Q1 results and Q2 guidance support the catalyst but do not remove this concentration risk.
Among recent announcements, Nova’s January 2026 update that leading chipmakers adopted the Metrion platform for gate all around and advanced DRAM stands out. Paired with Q1 2026’s record revenue of US$235.31 million and strong Q2 guidance, this suggests those earlier technology wins are now showing up in reported numbers, which matters directly for the thesis that Nova’s newer platforms can deepen its role at key advanced node and memory customers.
Yet even with these strong updates, investors should still be aware that...
Read the full narrative on Nova (it's free!)
Nova's narrative projects $1.4 billion revenue and $438.7 million earnings by 2029.
Uncover how Nova's forecasts yield a $497.25 fair value, in line with its current price.
Before this record quarter, the most pessimistic analysts were still modeling Nova to reach about US$1.3 billion in revenue and US$413.4 million in earnings by 2029, so you should recognize how differently people can view the same story and consider how these cautious assumptions about advanced node and memory demand might shift after the latest results.
Explore 4 other fair value estimates on Nova - why the stock might be worth less than half the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com